Univariable and multivariable Cox regression gene analysis for OS and EFS
| . | Cox regression . | |||||||
|---|---|---|---|---|---|---|---|---|
| Univariable . | Multivariable . | |||||||
| P . | HR . | 95% CI . | P . | HR . | 95% CI . | |||
| Lower . | Upper . | Lower . | Upper . | |||||
| Overall survival | ||||||||
| CEBPA single-mutated | .81 | 0.94 | 0.54 | 1.63 | ||||
| CEBPA double-mutated | .001 | 0.29 | 0.14 | 0.62 | .002 | 0.29 | 0.14 | 0.63 |
| NPM1mut/FLT3-ITD− | < .001 | 0.55 | 0.42 | 0.73 | .002 | 0.62 | 0.46 | 0.84 |
| NPM1mut/FLT3-ITD+ | .48 | 1.14 | 0.8 | 1.63 | ||||
| MLL-PTD | .009 | 1.71 | 1.15 | 2.55 | .117 | 1.39 | 0.92 | 2.08 |
| RUNX1 | .005 | 1.46 | 1.12 | 1.89 | .23 | 1.19 | 0.90 | 1.57 |
| ASXL1 | < .001 | 1.62 | 1.24 | 2.1 | .005 | 1.50 | 1.13 | 1.99 |
| TP53 | < .001 | 3.49 | 2.65 | 4.59 | < .001 | 3.01 | 2.23 | 4.05 |
| Event-free survival | ||||||||
| CEBPA single-mutated | .77 | 0.93 | 0.57 | 1.51 | ||||
| CEBPA double-mutated | .007 | 0.51 | 0.31 | 0.83 | .004 | 0.48 | 0.29 | 0.79 |
| NPM1mut/FLT3-ITD− | .001 | 0.7 | 0.56 | 0.87 | .01 | 0.73 | 0.57 | 0.93 |
| NPM1mut/FLT3-ITD+ | .87 | 0.97 | 0.7 | 1.35 | ||||
| MLL-PTD | < .001 | 1.98 | 1.4 | 2.81 | .006 | 1.65 | 1.12 | 2.36 |
| RUNX1 | .016 | 1.33 | 1.1 | 1.7 | .14 | 1.21 | 0.94 | 1.55 |
| ASXL1 | .064 | 1.26 | 1.0 | 1.6 | ||||
| TP53 | < .001 | 2.96 | 2.27 | 3.85 | < .001 | 2.51 | 1.90 | 3.30 |
| . | Cox regression . | |||||||
|---|---|---|---|---|---|---|---|---|
| Univariable . | Multivariable . | |||||||
| P . | HR . | 95% CI . | P . | HR . | 95% CI . | |||
| Lower . | Upper . | Lower . | Upper . | |||||
| Overall survival | ||||||||
| CEBPA single-mutated | .81 | 0.94 | 0.54 | 1.63 | ||||
| CEBPA double-mutated | .001 | 0.29 | 0.14 | 0.62 | .002 | 0.29 | 0.14 | 0.63 |
| NPM1mut/FLT3-ITD− | < .001 | 0.55 | 0.42 | 0.73 | .002 | 0.62 | 0.46 | 0.84 |
| NPM1mut/FLT3-ITD+ | .48 | 1.14 | 0.8 | 1.63 | ||||
| MLL-PTD | .009 | 1.71 | 1.15 | 2.55 | .117 | 1.39 | 0.92 | 2.08 |
| RUNX1 | .005 | 1.46 | 1.12 | 1.89 | .23 | 1.19 | 0.90 | 1.57 |
| ASXL1 | < .001 | 1.62 | 1.24 | 2.1 | .005 | 1.50 | 1.13 | 1.99 |
| TP53 | < .001 | 3.49 | 2.65 | 4.59 | < .001 | 3.01 | 2.23 | 4.05 |
| Event-free survival | ||||||||
| CEBPA single-mutated | .77 | 0.93 | 0.57 | 1.51 | ||||
| CEBPA double-mutated | .007 | 0.51 | 0.31 | 0.83 | .004 | 0.48 | 0.29 | 0.79 |
| NPM1mut/FLT3-ITD− | .001 | 0.7 | 0.56 | 0.87 | .01 | 0.73 | 0.57 | 0.93 |
| NPM1mut/FLT3-ITD+ | .87 | 0.97 | 0.7 | 1.35 | ||||
| MLL-PTD | < .001 | 1.98 | 1.4 | 2.81 | .006 | 1.65 | 1.12 | 2.36 |
| RUNX1 | .016 | 1.33 | 1.1 | 1.7 | .14 | 1.21 | 0.94 | 1.55 |
| ASXL1 | .064 | 1.26 | 1.0 | 1.6 | ||||
| TP53 | < .001 | 2.96 | 2.27 | 3.85 | < .001 | 2.51 | 1.90 | 3.30 |
Univariable and multivariable Cox regression analysis for OS and EFS of the genes CEBPA (both single- and double-mutated), NPM1mut/FLT3-ITD−, NPM1mut/FLT3-ITD+, MLL-PTD, RUNX1, ASXL1, and TP53.
OS indicates overall survival; EFS, event-free survival; CI, confidence interval; and HR, hazard ratio.